Inovio Pharmaceuticals (INO) Getting Somewhat Favorable Press Coverage, Analysis Finds
Press coverage about Inovio Pharmaceuticals (NASDAQ:INO) has been trending somewhat positive on Monday, according to Accern. Accern rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Inovio Pharmaceuticals earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 68 out of 100, meaning that recent news coverage is likely to have an effect on the stock’s share price in the next few days.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- Tardigrades: Unlikely Last Survivors on Earth (theaviationweek.net)
- Inovio Pharmaceuticals, Inc. – StreetInsider.com (streetinsider.com)
- Core Laboratories NV (NYSE:CLB) Valuation According To Analysts (leisuretravelaid.com)
- Synthetic DNA-based Zika vaccine protects against damage to testes in preclinical models (sciencedaily.com)
- New DNA-based vaccine protects testes, sperm from Zika-related damage in mouse models (news-medical.net)
Several brokerages recently weighed in on INO. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price objective on the stock in a report on Tuesday, July 11th. HC Wainwright set a $13.00 price objective on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Friday, July 7th. Maxim Group set a $12.00 price objective on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, June 8th. Piper Jaffray Companies upgraded shares of Inovio Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $14.00 price objective on the stock in a report on Thursday, June 8th. Finally, ValuEngine upgraded shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. Inovio Pharmaceuticals presently has an average rating of “Buy” and an average price target of $19.90.
Shares of Inovio Pharmaceuticals (NASDAQ:INO) traded down 0.565% during midday trading on Monday, reaching $7.915. 179,477 shares of the company’s stock traded hands. The stock’s market cap is $590.67 million. Inovio Pharmaceuticals has a 52-week low of $5.83 and a 52-week high of $11.00. The stock has a 50-day moving average price of $7.75 and a 200-day moving average price of $6.89.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.31). The firm had revenue of $10.40 million for the quarter, compared to the consensus estimate of $5.83 million. Inovio Pharmaceuticals had a negative net margin of 235.91% and a negative return on equity of 65.97%. The company’s revenue for the quarter was up 28.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.11) EPS. Analysts forecast that Inovio Pharmaceuticals will post ($1.10) earnings per share for the current year.
In other news, Director David B. Weiner sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $8.00, for a total value of $64,000.00. Following the transaction, the director now owns 740,956 shares in the company, valued at approximately $5,927,648. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.60% of the stock is currently owned by insiders.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.